Tumor angiogenesis as a therapeutic target

Area of Science:

• Pharmacology and Drug Discovery
• Oncology
• Biochemistry

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and has become a major focus in pharmacological research.
• Extensive research has elucidated the complex physiological, biochemical, and molecular mechanisms underlying angiogenesis.
• Over 300 drug candidates targeting angiogenesis are currently undergoing various stages of testing.

Purpose of the Study:

• To review advanced drug candidates for angiogenesis modulation currently in preclinical or clinical development.
• To highlight promising therapeutic strategies in the field of angiogenesis research.
• To provide an overview of the current landscape of anti-angiogenesis drug discovery.

Main Methods:

• Focus on drug candidates in advanced preclinical or clinical development stages.
• Review of scientific literature and industry pipelines related to angiogenesis inhibitors.
• Exclusion of early-stage academic and biotechnology research to maintain focus.

Main Results:

• A significant number of drug candidates (>300) are in development for modulating angiogenesis.
• The review emphasizes advanced projects, including those in preclinical and clinical trials.
• No drug currently on the market offers clinical benefit through selective angiogenesis modulation or inhibition.

Conclusions:

• Despite extensive research and numerous drug candidates, the clinical translation of selective angiogenesis inhibitors remains a challenge.
• The field holds significant therapeutic potential, but further advancements are needed for successful clinical application.
• Continued research and development are essential to overcome existing hurdles in bringing anti-angiogenesis therapies to patients.